Program Overview: Systematic Skeletal Phenotyping and Data Integration of Knockout Mouse Lines
Scientific Rationale
The genetic determinants that shape skeletal architecture, composition, and mechanical strength remain incompletely defined. While numerous genes are known to influence bone development and remodeling, the majority of protein-coding genes have not been systematically evaluated for their role in skeletal biology. This gap limits our understanding of complex skeletal diseases and constrains therapeutic innovation.
Large-scale functional genomics efforts that generate knockout mouse lines for individual genes provide an unprecedented opportunity to interrogate gene function across the entire genome. Given the high degree of conservation between mouse and human genomes, skeletal phenotypes observed in mouse models offer critical insight into human bone biology and disease mechanisms.
Systematic Skeletal Phenotyping Strategy
We undertake a comprehensive and standardized approach to evaluate the skeletal phenotype of each genetically altered mouse line. Our framework integrates:
- Quantitative bone structural analysis
- Static and dynamic bone histomorphometry
- Assessment of bone remodeling parameters
- Evaluation of architectural and compositional changes
This systematic strategy enables identification of genes that regulate bone mass, microarchitecture, turnover, and tissue-level organization. By applying consistent methodologies across lines, we ensure comparability, reproducibility, and high-resolution characterization of gene-specific skeletal effects.
Creation of an Integrated Bone Phenotype Repository
The rapid expansion of skeletal phenotyping efforts has generated substantial data across independent laboratories and large-scale initiatives. However, bone histomorphometry datasets remain dispersed and difficult to compare across studies.
To address this limitation, we are establishing a centralized, curated repository that aggregates bone phenotype and histomorphometry data from mutant mouse lines. This resource is designed to:
- Enable cross-model comparison of skeletal phenotypes
- Facilitate identification of shared molecular pathways
- Support large-scale meta-analyses
- Promote data transparency and reproducibility
- Accelerate translational discovery in skeletal biology
We invite investigators to contribute their histomorphometry datasets and skeletal analyses to build a comprehensive, community-driven resource that advances understanding of gene function in the skeleton.
Impact of Skeletal Diseases on Human Health and Health Care Systems
The Personal and Societal Burden
Heritable and degenerative skeletal diseases profoundly affect millions of individuals worldwide. Although most skeletal conditions are not immediately life-threatening, they are frequently chronic, painful, and progressively disabling. These disorders limit mobility, compromise independence, and significantly diminish both physical and mental well-being. The cumulative impact on quality of life is substantial and long lasting.
Musculoskeletal disorders consistently rank among the leading causes of disability globally. Their chronic nature means that affected individuals often require long-term management rather than curative treatment, amplifying both personal and societal consequences.
Economic Consequences
Beyond individual suffering, skeletal diseases impose one of the largest economic burdens of any diagnostic disease category. According to reports from the Bone and Joint Initiative, expenditures related to musculoskeletal conditions account for a significant proportion of national health care spending—estimated at approximately 7% of the total gross national product when direct medical costs and associated economic losses are considered.
Because most current therapies are not curative but instead aim to manage symptoms or slow progression, these disorders generate sustained, lifelong costs. The economic burden arises not only from medical treatment but also from reduced productivity, disability, rehabilitation services, and long-term care.
Limitations of Current Treatment Approaches
Present interventions largely focus on managing established disease rather than preventing its onset. Pharmacologic therapies, physical rehabilitation, and surgical procedures can mitigate symptoms, yet they do not eliminate the underlying vulnerability of skeletal tissue. As a result, patients often face progressive functional decline despite ongoing treatment.
To reduce the long-term economic and societal impact of skeletal diseases, a shift toward prevention and early risk identification is essential.
The Case for Early Identification and Prevention
Preventive strategies depend on identifying individuals at elevated risk before clinical symptoms appear. Once identified, at-risk individuals can:
- Modify physical behaviors to reduce tissue strain
- Implement lifestyle interventions that strengthen skeletal integrity
- Initiate targeted pharmacologic strategies when appropriate
A compelling example is osteoporosis. Twin studies demonstrate that peak bone mass—largely influenced by genetics and achieved during adolescence—is a strong predictor of fracture risk later in life. Because peak bone mass is accumulated during childhood and adolescence, susceptibility to osteoporosis in old age is strongly shaped decades earlier. In this sense, osteoporosis can be viewed as a disease with pediatric origins.
This perspective underscores the importance of identifying genetic predispositions to suboptimal bone acquisition early in life, when interventions can meaningfully alter long-term outcomes.
The Role of Basic Research
Achieving effective prevention requires reliable genetic and biological markers that predict adult skeletal disease risk. The fundamental challenge for the basic research community is therefore to:
- Identify genes and molecular pathways that regulate bone development and remodeling
- Define genetic variants associated with impaired peak bone mass
- Translate these discoveries into predictive markers usable in clinical practice
By providing primary care providers with validated genetic and biological indicators of risk, it becomes possible to intervene early—transforming skeletal disease management from reactive treatment to proactive prevention
Overview of Skeletal Phenotyping Efforts
A Systematic Approach to Functional Skeletal Genomics
To define the genetic determinants of bone architecture and remodeling, we have implemented a multi-phase skeletal phenotyping program focused on knockout mouse lines generated through large-scale functional genomics initiatives. Our efforts combine high-throughput screening with targeted deep phenotyping to identify genes that influence skeletal development, structure, and turnover.
This program encompasses both viable knockout lines and genetically altered models in which complete gene deletion results in embryonic lethality.
Broad-Based Screening of Viable Knockout Lines
An initial large-scale effort focused on the skeletal analysis of over two hundred viable knockout mouse lines selected from genome-wide gene disruption initiatives. Selection was largely determined by availability to enable broad, unbiased coverage of gene function.
For each line:
- Male and female mice were analyzed at 12 weeks of age (n = 8 per sex).
- Animals received mineralization labels prior to analysis to assess dynamic bone formation.
- High-resolution micro–computed tomography (micro-CT) was used as a primary screening tool.
- Lines exhibiting significant deviations in bone structural parameters underwent comprehensive static and dynamic bone histomorphometry.
This systematic screening strategy enabled the identification of previously unrecognized genes that regulate bone mass, microarchitecture, and remodeling dynamics.
Targeted Analysis of Essential Genes and Subviable Models
Recognizing that many genes critical to skeletal biology are essential for survival, the current phase of our work extends phenotyping to heterozygous knockout mice for genes that are embryonic lethal or postnatally subviable in the homozygous state.
Selection criteria for these lines include:
- Gene expression profiles suggestive of skeletal relevance
- Biological novelty
- Preliminary phenotypic signals from large-scale screening consortia
- Known involvement in developmental or signaling pathways
Heterozygous animals are evaluated at 12 weeks of age (n = 8 per sex) using the same standardized pipeline:
- Micro-CT screening to detect alterations in bone mass and structure
- Follow-up static and dynamic histomorphometry for lines with significant skeletal deviations
In addition, limited skeletal assessments are performed on late-stage homozygous embryos to characterize developmental skeletal abnormalities associated with complete gene disruption.
Integrated Phenotyping Pipeline
Across all phases of investigation, we employ a consistent and reproducible phenotyping workflow:
- Age- and sex-controlled cohorts
- Fluorochrome-based dynamic labeling
- Quantitative micro-CT analysis
- Static and dynamic histomorphometry
This standardized framework allows for cross-line comparison, enhances reproducibility, and strengthens the ability to identify gene-specific effects on skeletal structure and remodeling.